Article Versions Notes

Kurihara E, Kakizaki S, Ijima M, Hatanaka T, Kubo N, Suzuki Y, Yasuoka H, Hoshino T, Naganuma A, Tani N, et al. Efficacy and Safety of the Combination of Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: A Real-World Retrospective Cohort Study. Biomedicines. 2025; 13(8):1915. https://doi.org/10.3390/biomedicines13081915

Kurihara, Eishin, Satoru Kakizaki, Masashi Ijima, Takeshi Hatanaka, Norio Kubo, Yuhei Suzuki, Hidetoshi Yasuoka, Takashi Hoshino, Atsushi Naganuma, Noriyuki Tani, and et al. 2025. "Efficacy and Safety of the Combination of Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: A Real-World Retrospective Cohort Study" Biomedicines 13, no. 8: 1915. https://doi.org/10.3390/biomedicines13081915

Kurihara, E., Kakizaki, S., Ijima, M., Hatanaka, T., Kubo, N., Suzuki, Y., Yasuoka, H., Hoshino, T., Naganuma, A., Tani, N., Yamazaki, Y., & Uraoka, T. (2025). Efficacy and Safety of the Combination of Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: A Real-World Retrospective Cohort Study. Biomedicines, 13(8), 1915. https://doi.org/10.3390/biomedicines13081915